PFS
CGEM icon

Prospera Financial Services’s Cullinan Oncology CGEM Stock Holding History

Prospera Financial Services’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,168
Closed -$12K – 1765
2022
Q1 		$12K Buy
+1,168
New +$15.8K ﹤0.01% 1945

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Prospera Financial Services's CGEM Position: Q2 2022 in Review

Prospera Financial Services sold out of Cullinan Oncology (CGEM) in Q2 2022, closing a stake of 1,168 shares — an estimated $12K sold.

Prospera Financial Services first reported a position in CGEM in Q1 2022 and held it in 1 quarter. The position peaked at $12K in Q1 2022. 89 funds tracked by Wall St. Rank hold CGEM as of Q2 2022.

  • Prospera Financial Services reported no remaining Cullinan Oncology position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 1,168 Cullinan Oncology shares in Q2 2022, an estimated $12K.
  • Prospera Financial Services first reported a position in Cullinan Oncology in Q1 2022 and held it in 1 quarter.
  • Prospera Financial Services's Cullinan Oncology position peaked at $12K in Q1 2022.
  • 89 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.